Achi news desk-
GUWAHATI: Global pharmaceutical giant AstraZeneca has admitted that its COVID-19 vaccine, Covishield, manufactured under license in India by the Serum Institute of India (SII), can cause thrombosis with thrombocytopenia syndrome (TTS), a condition characterized by blood clots and low platelets. Considered. The admission came during court proceedings related to lawsuits in the UK alleging the vaccine caused health complications and deaths.
TTS is a rare condition that occurs when blood clots form in blood vessels, which can lead to serious health risks such as strokes, heart attacks, and other complications. Symptoms of TTS can include shortness of breath, pain in the chest or limbs, red spots the size of a pinhead, or bruising on the skin.
Click here to join our WhatsApp channel
AstraZeneca’s court admission follows lawsuits filed by individuals and families seeking damages due to adverse reactions from the vaccine. According to UK media reports, one case was filed by a man who suffered brain damage after developing a blood clot following his vaccination in April 2021. In total, fifty-one cases were filed in the UK High Court, with compensation claims estimated to be worth up to £100 million.
While the Indian government published a fact sheet in January 2021 advising caution for those with thrombocytopenia, other countries temporarily stopped using AstraZeneca’s vaccine in March 2021 after reports of blood clotting. Until April 2021, the World Health Organization (WHO) recognized TTS as a rare event following Covishield vaccines.
Also Read: SC reserves judgment on Prabir Purkayastha’s plea challenging detention in UAPA case NewsClick
Despite these reports, the Ministry of Health of the Indian Union stated that the overall risk remains the same "tiny" And that cubbyshield "continues to have a distinctly positive benefit-risk profile." The ministry reported that 26 potential thromboembolic events, or the formation of blood clots in blood vessels, have been reported since the launch of Covishield in January 2021, equal to 0.61 cases per million doses. He also indicated that the risk of TTS in South and Southeast Asian descent is 70% lower than in those of European descent.
Recent data from India’s Committee on Adverse Events Following Immunization (AEFI) shows that 36 cases of TTS have been confirmed to be caused by Covishield, with 18 resulting in death. Most of these cases were reported in 2021, the first year of Covid-19 vaccines in India. No cases of thromboembolic events have been reported with Covaxin, Bharat Biotech’s domestic vaccine.
